CAR T Cell Immunotherapy for Lymphoma & Leukemia - T. Shea - 20160608
Dr. Thomas Shea, MD discusses the biology behind the use of Chimeric Antigen Receptor (CAR) for T cell Immunotherapy, including current indications and general results. Learning Outcomes: • Explain biology behind the use of Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy. • Describe the current indications for CAR-T cell therapy. • Discuss the general results with CAR-T cell therapy. This lecture was presented as a part of the Medical and Surgical Oncology Lecture Series and the RN and Allied Health Lectures.
Thomas Shea MD, Director of the UNC Cancer Network
6/8/2016 3:30:00 PM

Mediasite Showcase
Mediasite's the trusted cornerstone of any campus or enterprise video strategy. Our unyielding commitment to all things video helps you transform education, training, communications and online events.
Webcasting Video Content Management Video Delivery Integration Services Mediasite Community
Powered By Mediasite - Enterprise Video Platform
Sonic Foundry